Dr. Partha Dutta is an assistant professor in the Department of Medicine at the University of Pittsburgh. He did his PhD at the University of Wisconsin Madison, and a postdoctoral fellowship at Massachusetts General Hospital. He worked as an instructor at Harvard Medical School before joining the University of Pittsburgh. His current research interests focus on the immunology of cardiovascular and metabolic diseases. He is investigating how myeloid cells, such as monocytes and macrophages, induce inflammation. Innate inflammatory cells, such as monocytes and macrophages, are important in cardiovascular disease. After being recruited to atherosclerotic plaques or myocardial infarcts, myeloid cells secrete proteolytic enzymes, e.g., cathepsin and matrix metalloproteinase that digest the extracellular matrix, render atherosclerotic plaques unstable and dilate the myocardium. This results in heart failure or plaque rupture, which triggers a secondary myocardial infarction. Although newly recruited cardiac macrophages are well known for aggravating inflammation after MI, the mechanisms of why these macrophages are inflammatory are not well known. Dr. Dutta’s long term goal is to understand the cross talk among cellular metabolism, epigenetics and inflammation. His ultimate goal is to identify therapeutic targets in these processes and develop therapeutic avenues for patients with MI by targeting metabolic pathways in macrophages.
Dr. Partha Dutta is an assistant professor in the Department of Medicine at the University of Pittsburgh. He did his PhD at the University of Wisconsin Madison, and a postdoctoral fellowship at Massachusetts General Hospital. He worked as an instructor at Harvard Medical School before joining the University of Pittsburgh. His current research interests focus on the immunology of cardiovascular and metabolic diseases. He is investigating how myeloid cells, such as monocytes and macrophages, induce inflammation. Innate inflammatory cells, such as monocytes and macrophages, are important in cardiovascular disease. After being recruited to atherosclerotic plaques or myocardial infarcts, myeloid cells secrete proteolytic enzymes, e.g., cathepsin and matrix metalloproteinase that digest the extracellular matrix, render atherosclerotic plaques unstable and dilate the myocardium. This results in heart failure or plaque rupture, which triggers a secondary myocardial infarction. Although newly recruited cardiac macrophages are well known for aggravating inflammation after MI, the mechanisms of why these macrophages are inflammatory are not well known. Dr. Dutta’s long term goal is to understand the cross talk among cellular metabolism, epigenetics and inflammation. His ultimate goal is to identify therapeutic targets in these processes and develop therapeutic avenues for patients with MI by targeting metabolic pathways in macrophages.